Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study
Miauton A, Audran R, Besson J, Hajjami H, Karlen M, Warpelin-Decrausaz L, Sene L, Schaufelberger S, Faivre V, Faouzi M, Hartley M, Spertini F, Genton B. Safety and immunogenicity of a synthetic nanoparticle-based, T cell priming peptide vaccine against dengue in healthy adults in Switzerland: a double-blind, randomized, vehicle-controlled, phase 1 study. EBioMedicine 2023, 99: 104922. PMID: 38128414, PMCID: PMC10776924, DOI: 10.1016/j.ebiom.2023.104922.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, ViralDengueDouble-Blind MethodGoldHumansMetal NanoparticlesPeptidesSwitzerlandVaccines, SyntheticConceptsCD8+ T cellsT cellsDouble-blindIntention-to-treatVehicle-controlledAdverse eventsVirus-specific CD8+ T cellsPeptide vaccinesCD8+ T cell immunityInjection site erythemaInjection site painT cell immunityPhase 1 studyPhase 1 trialDengue vaccine candidateAnti-DENV antibodiesAntibody-dependent enhancementSite painSevere dengueGlobal health threatCentral memoryPrimary outcomeCD8Microneedle injectionInduced antibodies